Three questions on… desogestrel and panic attacks

Signal detection / 30 October 2018

Ball-and-stick model of the desogestrel molecule, a progestin used in birth control pills. Illustration: Medgirl131, Wikimedia

UMC’s Research pharmacist Sarah Watson explains the significance of a recently published signal that links contraceptive drug desogestrel to panic attacks.

What is special about this signal?

Hormonal contraceptives are widely used by women around the world, and most women who take these drugs are healthy, so their acceptance of adverse effects will be low. Panic attacks can seriously reduce a person’s quality of life, but if we know what’s causing them, we can prevent them.

How did you identify the signal?

It emerged during a signal detection workshop that UMC held with the Netherlands Pharmacovigilance Centre Lareb in 2016, where we focused on patient reports in VigiBase. The reports, submitted mainly by patients, with a few from healthcare professionals, described the occurrence of panic attacks and panic reactions after taking the commonly used oral contraceptive desogestrel (sold under several trade names, such as Cerazette). The case narratives, and the patient stories they contained, were essential for us to understand how the adverse reactions impacted on patients’ lives – we even decided to include quotes from patients in our publication, to illustrate their importance. 

What are you hoping to achieve with this publication?

We hope to spread the information to a wider audience – that’s why we decided to publish it as an open-access article in an online journal. Most medicines safety issues identified by UMC are communicated through the SIGNAL document, which is restricted to members of the WHO Programme for International Drug Monitoring, and through the publicly available WHO Pharmaceuticals Newsletter. Occasionally, some signals are disseminated further. It is our hope that women on desogestrel, searching for more information on this contraceptive and panic attacks on the Internet, find our publication. 

Sarah Watson
Research Pharmacist, UMC

You may also like

Record growth pushes VigiBase past 28 million reports

After decades of slow but steady growth, VigiBase has recently entered a new phase of accelerating expansion, driven by a range of converging forces.

Signal detection / 16 September 2021

Unmasking data in the COVID-19 vaccine era – New podcast episode

What are the implications for signal detection when new approaches to reporting create greater data streams than have ever been present for older medicinal products?

Signal detection / 30 January 2023

Vaccine surveillance systems explained – new podcast episode

Ever wondered how safety surveillance differs between vaccines and drugs? Find out in the latest episode of the Drug Safety Matters podcast.

Signal detection / 25 August 2022

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies.

Find out more